UltraScreen® eReport™
Early Detection, Early Reassurance
UltraScreen® eReport™ enables trained medical professionals to present a complete risk assessment for Down syndrome and trisomy 18/13 during a single office visit and ensure same-day results notification for the patient. Performed between 9 to 13 weeks, 6 days from conception, the Ultra-Screen free Beta/PAPP-A/NT screen provides a care path for Down syndrome risk assessment that is logistically simple to integrate within your overall prenatal care plan.
In the earlier stages of the pregnancy (9 to 11 weeks, 1 day), your patient will provide a dried blood sample obtained through a simple, safe finger stick method. Venous blood may be used, yet dried blood sampling provides a more beneficial way to collect, store and process maternal blood specimens. Maternal blood samples are spotted onto an absorbent test card. This test card also functions as a hard-copy data record of the patient’s information including history, billing information, ultrasound dates and consent. After the blood spot collection is done, the cards are sent directly to NTD Labs where they are processed, tested and archived according to protocol.
The results of the blood screen are maintained at NTD Labs and made available to the physician when the patient undergoes her NT (and optional fetal nasal bone assessment) ultrasound exam between 11 weeks, 1 day and 13 weeks, 6 days. To save time, NTD Labs provides web-based access to your patient’s biochemistry data through a secure UltraScreen® eReport™ website. This site provides information management tools that allow you to call up individual patient records, enter key biophysical data from the ultrasound, and then present a “complete” risk assessment for Down syndrome a day within the patient’s visit. The calculation is based upon your patient’s data, so there is less guess work involved and less time spent between results reporting and patient notification.
The benefits of the UltraScreen® eReport™ Program:
- Early reassurance – since 95% of all pregnant patients are shown to be a low risk, UltraScreen® eReport™ helps alleviate unnecessary anxiety for the patient and her family by providing early answers in the first trimester.
- More time to assess options – those women shown to be at increased risk can receive immediate counseling regarding possible follow-up diagnostics such as CVS and amniocentesis.